Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Receivables - Other (2020 - 2023)

Historic Receivables - Other for Mereo BioPharma (MREO) over the last 4 years, with Q4 2023 value amounting to $2.0 million.

  • Mereo BioPharma's Receivables - Other changed N/A to $2.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $2.0 million, marking a year-over-year change of. This contributed to the annual value of $2.0 million for FY2023, which is N/A changed from last year.
  • Per Mereo BioPharma's latest filing, its Receivables - Other stood at $2.0 million for Q4 2023.
  • In the past 5 years, Mereo BioPharma's Receivables - Other ranged from a high of $2.3 million in Q2 2020 and a low of $1.3 million during Q2 2022
  • Over the past 4 years, Mereo BioPharma's median Receivables - Other value was $1.7 million (recorded in 2021), while the average stood at $1.7 million.
  • Over the last 5 years, Mereo BioPharma's Receivables - Other had its largest YoY gain of 4258.04% in 2021, and its largest YoY loss of 3685.02% in 2021.
  • Over the past 4 years, Mereo BioPharma's Receivables - Other (Quarter) stood at $1.3 million in 2020, then soared by 42.58% to $1.9 million in 2021, then plummeted by 33.51% to $1.3 million in 2022, then skyrocketed by 53.31% to $2.0 million in 2023.
  • Its last three reported values are $2.0 million in Q4 2023, $1.3 million for Q2 2022, and $1.9 million during Q4 2021.